INTRODUCTION
Heparin-induced thrombocytopenia (HIT) is a rare, but severe complication of heparin therapy. 1 HIT is caused by heparin-dependent antibodies (typically IgG), which are directed against a molecular complex formed by heparin and the platelet alpha-granule protein, platelet factor 4.
1
These IgG immune complexes bind to the Fc gamma IIa receptors on the platelet surface, resulting in platelet activation and aggregation, and eventually, to the occurrence of both thrombocytopenia and thrombosis. For patients with HIT, treatment with heparin must be stopped and an alternative antithrombotic agent used. Low-molecular-weight heparins cannot be used since they also crossreact, although to a lesser extent, with HIT-associated antibodies. 1 Fondaparinux (Arixtra ® ), a new synthetic and selective inhibitor of coagulation factor Xa, 2, 3 has been shown to be an effective and safe antithrombotic agent in a number of thrombotic disorders. [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] No episodes of HIT were reported in the large phase II and III clinical program. This result is consistent with the fact that, in vitro, fondaparinux did not cross react with HIT-associated antibodies. [14] [15] [16] [17] However, these in vitro studies using a limited set of sera and different methodologies of variable sensitivity and specificity, did not permit a definitive conclusion to be made regarding the safety of fondaparinux in terms of its ability to induce platelet activation in the presence of HIT-associated antibodies.
Currently, besides immunoenzymoassays that measure antibodies to heparin-platelet factor 4 complex, three functional assays are used in vitro to investigate the effect of HIT-associated antibodies on platelet function, namely serotonin release assay (SRA), considered to be the gold standard, 18 heparin-induced platelet agglutination assay (HIPA), 19 and platelet aggregation test. 20 These biological assays are difficult to perform and to interpret. 1, 21 Additionally, there may be advantages in performing all assays together to further enhance sensitivity and specificity. 21 Using these three assays, we compared in a blinded manner, the effect of fondaparinux with that of unfractionated heparin on platelet activation and aggregation in the presence of sera collected from
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5 patients with clinically-documented HIT. The effect of fondaparinux on platelet activation in the presence of HIT sera was further assessed using sensitive flow cytometry techniques to measure the expression of specific platelet activation-related markers on the platelet surface. [22] [23] [24] For personal use only. 
MATERIALS AND METHODS
Study design
Sera from patients with laboratory-confirmed HIT (HIT sera) and from subjects without HIT (control sera) were collected in three centers (Appendix). The local institutional review boards at the Prince of Wales Hospital, the Universitat Griefswald, and the Hopital Trousseau each approved this study and obtained informed consent according to the Declaration of Helsinki. All the sera were then aliquoted and a sub-sample sent to a predetermined reference laboratory (Appendix) for characterization. This laboratory performed both enzyme immunoassays plus SRA on all of these samples to confirm positive or negative results. These independently verified sera were then sent to the central laboratory. The central laboratory then sent out the positive HIT sera and negative control sera, in a coded and blinded fashion, to the three participating test laboratories (Appendix).
All of the three test laboratories were also provided with solutions of buffer, unfractionated heparin and fondaparinux for the serotonin release, the platelet agglutination and the platelet aggregation assays. One specific assay was performed per centre. All investigators were blinded about the type of serum and the type of test solution. All blood donors had given written informed consent.
Sera
A first set of sera was obtained from 45 patients diagnosed with HIT. These patients had HIT defined by a fall in the platelet count to less than 100 x 10 9 /L or a 50% decrease in platelet count, five or more days after starting heparin. Other causes of thrombocytopenia (ie: autoimmune thrombocytopenia, secondary immune thrombocytopenia, drug dependent thrombocytopenia and infection dependent thrombocytopenia) were excluded, according to clinical diagnosis. The HIT sera were all positive in the designed reference laboratory. A second set of sera was obtained from 15 healthy volunteers not receiving heparin or other agents known to affect the coagulation system.
All sera collected from patients with HIT, positive on SRA and confirmed to have antibodies 7 against heparin-platelet factor 4 (HIT-IgG) by the reference laboratory, were categorized as "HIT serum". All sera collected from healthy subjects, negative on SRA and in which the absence of HIT-IgG was confirmed by the reference laboratory, were designated as "control serum". Before use, the sera were heated at 56°C for 30 minutes to inactivate complement and traces of thrombin.
Except for confirmatory testing, the reference laboratory was not part of the laboratory testing.
Unfractionated heparin and fondaparinux
Solutions of various concentrations of unfractionated heparin (Calciparine 
Immunoenzymoassay for antibodies to heparin-platelet factor 4 complex
The presence of antibodies to heparin-platelet factor 4 complex (HIT-IgG) was investigated using an immunoenzymoassay described previously. 25 Purified platelet factor 4 (20 µg/mL, R&D the amount of 14 C-serotonin released into the supernatant was measured using a scintillation counter after centrifugation (1800g, 5 minutes). The result was considered as "positive" with unfractionated heparin when the release of 14 C-serotonin was more than 20% at 0.1, 0.3 or 1 IU/mL unfractionated heparin and less than 20% at 100 IU/mL unfractionated heparin. For fondaparinux, a result was considered as "positive" when the release was more than 20% at 0.1, 0.3, 1.0 or 3.0µg/mL fondaparinux and less than 20% at 100 µg/mL fondaparinux. If the release was greater than 20% in the presence of buffer, 100 IU/mL unfractionated heparin, or 100µg/mL fondaparinux, the result was considered as "indeterminate". In all other cases, the result was considered as "negative". The 
Heparin-Induced Platelet Agglutination Assay
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9 HIPA was performed as previously described. 26 Platelet-rich plasma was prepared by centrifugation (120g, 20 minutes) from citrated blood (ACD, 1.6/8.4, v/v) from healthy donors who had not taken any medication within the previous 10 days. Apyrase (grade IV, 5 µL at 1000 U/mL, Sigma, Munich, Germany) was added, and platelets were washed and resuspended in tyrode buffer (pH 6.3) containing 2.5 U/mL apyrase and 1 U/mL hirudin (Pentapharm, Basel, Switzerland). After incubation in sealed tubes at 37°C for 15 minutes, platelets were centrifuged (650g, 7 minutes),
resuspended to obtain a platelet concentration of 300-400 x 10 9 /L in 1 mL of suspension buffer donors, the result was considered as "indeterminate". In all other cases, the result was considered as "negative".
Platelet Aggregation
Platelet aggregation was performed as previously described. 27 Platelet-rich plasma, obtained by centrifugation (150g, 10 minutes) of whole blood collected in citrate (0.129 mol/L, 1/9, v/v) 10 from healthy individuals who had not taken aspirin within the seven days preceding blood collection, was adjusted to 300 x 10 9 /L. Platelet aggregation was measured at 37°C using an aggregometer (Platelet Aggregation Profiler, BioData, Horsham, PA). The ability of donor platelets to aggregate was first tested in the presence of collagen (70 µg/mL, Stago, Asnières, France). Then, platelet-rich plasma was incubated with sera and solutions of buffer, unfractionated heparin or fondaparinux. Aggregation was considered as positive when it exhibited a sharp initial slope (>20%/minute) and a maximum level of aggregation of 50% or more within 20 minutes. For unfractionated heparin, the result was considered as "positive" when platelet aggregation occurred with 0.1, 0.3 or 1 IU/mL unfractionated heparin, but not with 100 IU/mL unfractionated heparin.
For fondaparinux, the result was "positive" when platelet aggregation occurred at 0.1, 0.3, 1.0 or 3.0µg/mL fondaparinux, but not with 100 µg/mL fondaparinux. If platelet aggregation occurred in the presence of buffer, 100 IU/mL unfractionated heparin, or 100µg/mL fondaparinux, the result was considered as "indeterminate". In all other cases, the result was considered as "negative", but before concluding the result was negative, platelet-rich plasma from at least two different donors were tested.
Flow Cytometry Analysis
Platelet-rich plasma was prepared by centrifugation (100g, 5 minutes) from citrated blood 
Statistical Analysis
The statistical analysis was performed using a logit model, assuming the binomial distribution of the response, including the three assays (SRA, HIPA, and platelet aggregation) and treatments (unfractionated heparin and fondaparinux) as fix factors.
For
RESULTS
Characterization of the sera
Sera were collected from 15 healthy subjects without HIT and 45 patients with documented HIT. The reference laboratory reported that SRA was negative in all 15 sera obtained from healthy subjects, and none contained antibodies to heparin-platelet 4 complex. SRA was negative in 6 of the 45 sera collected from patients with HIT. All the 39 remaining HIT sera gave positive results.
Control Sera
Using SRA at another reference laboratory, one control serum (6.7%) was positive with 0.1 IU/mL of unfractionated heparin; all other sera were negative, regardless of the compound tested (Table 1) . Using HIPA, all control sera were negative with unfractionated heparin or fondaparinux.
Platelet aggregation results were indeterminate with 4 sera (26.7%), platelets aggregating with 100 IU/mL unfractionated heparin. Out of 11 remaining sera, platelet aggregation was positive with one control serum (9.1%) in the presence of 0.3 IU/mL unfractionated heparin.
HIT Sera
The results of the three types of platelet assays for heparin-dependent anti-platelet antibodies on the sera obtained from 39 patients with HIT in the presence of buffer or various concentrations of unfractionated heparin or fondaparinux are shown in Tables 1 and 2 .
Serotonin Release Assay
SRA results were indeterminate for 5 HIT sera, leaving 34 evaluable sera. SRA was positive in 26 of these sera (76.5%) with unfractionated heparin, but only in 2 sera with fondaparinux (5.9%). Interestingly, one serum testing positive with fondaparinux (serum 24) was negative with unfractionated heparin. In addition, the mean percentage of maximum serotonin release obtained 13 with unfractionated heparin was 65.7% (n=26, range: 25-100%) as compared to 33.5% with fondaparinux (n=2, 39% and 28%).
Heparin-Induced Platelet Agglutination Assay
HIPA results were indeterminate for 3 HIT sera, leaving 36 evaluable sera. Of those 33 sera (91.7 %) were positive with unfractionated heparin at low but not at high concentrations (100 IU/mL).
Of these 33 sera, 16 were negative with buffer and 17 reacted weakly with platelets without addition of heparin or fondaparinux. This reaction was strongly enhanced by heparin but not by fondaparinux with respect to the concentrations tested. However, the very high concentration of fondaparinux (100 µg/mL) inhibited the heparin independent platelet activating effect of HIT antibodies in 9 of 17 sera. These weak reactions in the absence of heparin might be due to unknown antibodies or platelet activating agents in patient sera, not related to HIT. Alternatively they may be HIT antibodies giving a weak positive reaction because of contamination with traces of heparin.
The effect of fondaparinux occurs only at high concentration and does not seem to be relevant for its anti Xa activity. Of the 16 sera not showing any platelet activating effect in the presence of buffer, 15 did not cause platelet activation in the presence of any of the fondaparinux concentrations tested. One serum showed a weak platelet activating effect in the presence of fondaparinux.
Platelet Aggregation
Platelet aggregation was not done in 6 samples due to insufficient amount of serum. The result was indeterminate with 9 HIT sera, leaving 24 evaluable sera. The test was positive in 16 sera (66.7%) with unfractionated heparin and in none with fondaparinux.
Statistical Analysis
For personal use only. on . by guest www.bloodjournal.org From With fondaparinux, the overall level of positive activity (without distinction of the methods) in the presence of HIT sera (3.3%, 3/91) was not different from that in the presence of control sera (0.0%, 0/41, p=0.91). In contrast, with unfractionated heparin, the overall level of positive activity was significantly (p<0.001) greater in the presence of HIT sera (79.8%, 75/94) than in the presence of control sera (2/41, 4.9%). In addition, in the presence of HIT sera, the level of positive activity was significantly (p<0.001) greater with unfractionated heparin than with fondaparinux (79.8% versus 3.3%, respectively).
Flow Cytometry Analysis
The results of the binding of PAC1 and anti-CD62 monoclonal antibodies or annexin V to the platelets in the presence of 14 HIT sera and various concentrations of unfractionated heparin and fondaparinux are shown in Table 3. PAC1 is a monoclonal antibody that recognizes the active conformation of human GpIIb-IIIa present at the platelet surface. The activation of GpIIb-IIIa is clearly correlated to the ability of the complex to bind soluble fibrinogen and result in platelet aggregation.
29
CD62 is an intra-platelet protein that is not present on the surface of resting platelets. It is stored in the membrane of the -granules and is exposed when these granules fuse with the external membrane. It can therefore be considered as a marker of platelet release.
30
Annexin V is a positively-charged protein, which binds to electronegative phospholipids such as phosphatidyl-serine. It is currently used as a probe for measuring the exposure of electronegative phospholipids allowing the platelet surface to trigger thrombin generation. in 14 (100%), 9 (64.3%, i.e. all sera except no. 4, 18, 32, 33, 39) and 13 (92.9%, i.e. all sera except no.4) HIT sera, respectively. In contrast, in the presence of fondaparinux, the mean binding of annexin V, PAC1 monoclonal antibody and anti-CD62 monoclonal antibody did not change, regardless of the fondaparinux concentration; none of the 14 HIT sera tested positive with fondaparinux, regardless of the fondaparinux concentration and the platelet activation membrane marker.
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DISCUSSION
Using three functional assays, our study shows that, in most cases, fondaparinux does not activate platelets in the presence of sera obtained from patients with HIT: the platelet aggregation test was negative with all evaluable sera, the HIPA test was positive with only one serum (3.0%) and the SRA was positive with only 5.9% of the HIT sera. In contrast, with unfractionated heparin, the results were positive with the three tests in approximately 67% to 92% of HIT sera. We suggest that our results are reliable for several reasons. First, the sera were carefully selected and characterized. Second, a combination of three reference complementary functional tests was used.
Third, all control and HIT sera were investigated in a blinded manner using a large range of fondaparinux and unfractionated heparin concentrations. Furthermore, the inability of fondaparinux to activate platelets in the presence of HIT sera was confirmed by the flow cytometry analysis of glycoprotein IIb-IIIa activation, dense granule release and expression of negatively-charged phospholipids on the platelet membrane, three highly sensitive markers of platelet activation.
There is variability among different biological assays in detecting the presence of heparindependent platelet antibodies. For this reason, we studied the ability of fondaparinux and unfractionated heparin to induce platelet activation in the presence of HIT sera using three reference functional assays. Compared to platelet aggregation performed in platelet-rich plasma, tests using washed platelets, e.g. HIPA and SRA, are generally considered to be the more sensitive for detecting heparin-dependent platelet antibodies.
The generation of HIT-related antigen has been shown to be dependent on the molecular weight of polysaccharides, the optimal chain length being sixteen saccharides.
14 Fondaparinux, a pentasaccharide, may therefore be considered to be too small to induce the expression of such antibodies. Indeed, the present study confirms that fondaparinux does not appear to interact with HIT-related antibodies to induce platelet activation and aggregation. This result differentiates fondaparinux from low-molecular-weight heparins, which show complete cross-reactivity with the antibodies that cause HIT and which are known to exacerbate HIT in those patients with preformed in which fondaparinux was given to approximately 5,000 patients. [4] [5] [6] [7] [8] [9] Moreover, some cases have been reported of successful treatment with fondaparinux of patients hypersensitive to heparin and low-molecular-weight heparin. 33, 34 In contrast, orthopedic patients treated with unfractionated heparin have about a 5% risk of HIT with at least half of the affected patients developing HITassociated thrombosis; the HIT risk with low-molecular-weight heparins in this setting has been estimated as 0.75%. The inability of fondaparinux to induce platelet activation in the presence of HIT sera was demonstrated in previous smaller studies. 14, 15 We confirm this finding over a large range of fondaparinux concentrations using three complementary qualitative assays. Furthermore, using flow cytometry, we show that the addition of fondaparinux to HIT sera and platelets did not result in platelet activation as measured using annexin V, activation of glycoprotein IIb-IIIa or the release of dense granules. Interestingly, among these three markers of platelet activation, annexin V was the most sensitive for detecting heparin-dependent platelet antibodies. The positivity of SRA with fondaparinux in two sera and of HIPA in one serum is of uncertain significance and its biological relevance is uncertain; of note, serum 24 was not positive with unfractionated heparin and serum 33
was negative when the binding of annexin V was studied in the presence of fondaparinux on flow cytometry. A previous study showed that, in contrast to unfractionated heparin, fondaparinux did not increase the binding of HIT-related antibodies to purified platelet factor 4. 16 The inability of fondaparinux to induce platelet activation in the presence of HIT may be related to the fact that this pentasaccharide does not have the minimal chain length and minimum charge per carbohydrate required for induction of the HIT antigen on platelet factor 4.
by the presence of IgG antibodies to heparin-platelet factor 4 complex. 35 The specificity of assays for heparin-dependent platelet activation was verified since samples were only categorized as positive if the positive results observed in the presence of clinically relevant heparin concentration were reversed in the presence of high concentrations of unfractionated heparin 1 ; in the case of heparin-dependent platelet activation, high concentrations of unfractionated heparin displace the heparin/platelet factor 4 complex from the platelet surface and the test becomes negative. 22 In conclusion, the safety of fondaparinux administration to patients in terms of HIT, which has yet to be firmly established clinically, may be an important advantage of fondaparinux over the heparins. Further, our study suggests that fondaparinux which does not enhance the platelet activation effect of HIT sera could be used as a treatment for HIT. 
